Overview

Helicobacter Pylori Eradication in Subjects With Non-alcoholic Fatty Liver Disease

Status:
Completed
Trial end date:
2013-06-01
Target enrollment:
0
Participant gender:
All
Summary
The aim of study was to evaluate the effect of helicobacter pylori eradication on liver function tests, lipid profile, homeostasis model assessment-IR (HOMA-IR) index, and anthropometric measurements (body mass index and waist circumference)in subjects with non-alcoholic fatty liver disease.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Tehran University of Medical Sciences
Collaborator:
Kashan University of Medical Sciences
Criteria
Inclusion Criteria:

- Dyspeptic patients with positive antibody to H.pylori and persistent elevated
aminotransferase levels with the evidence of fatty liver in ultrasonography, who were
referred to a gastroenterology clinic

Exclusion Criteria:

- Alcohol use (more than 20 gram per day in men and 10 gram per day in women per day),
heart disease (ischemic or congestive), hepatic disease (viral hepatitis, autoimmune
hepatitis, wilson disease, hemochromatosis, liver mass lesion), renal disease (serum
creatinine concentration of > 1.5 mg/dl), any severe systemic co-morbidities,
neoplasm, using any hepatotoxic medication during the past 3 months, previous history
of peptic ulcer, previous history of H.pylori eradication, and pregnant or lactating
women.